A Turning Point in Diagnostic Imaging
Medical imaging is one of the most data-rich domains in healthcare, and it has become the leading proving ground for artificial intelligence in clinical medicine. Radiology generates enormous volumes of structured visual data — CT scans, MRIs, X-rays, ultrasounds, pathology slides — that is amenable to the pattern recognition capabilities of deep learning algorithms. The combination of this data abundance, the measurability of diagnostic performance, and the genuine clinical need for faster and more consistent interpretation has made AI in medical imaging one of the most rapidly developing areas of health technology.
As of 2025, more than 700 AI algorithms have received regulatory clearance from the US Food and Drug Administration in the device software category. Many hundreds more have received CE marking in Europe, clearance in China, or approvals in other major markets. This is no longer an experimental frontier — AI tools for medical imaging are deployed clinical infrastructure in a growing number of radiology departments worldwide.
How AI Works in Medical Imaging
The dominant technique underlying most current clinical AI in imaging is convolutional neural networks (CNNs), a class of deep learning algorithm designed for image analysis. CNNs learn to recognise patterns in images by processing training data — typically thousands or millions of labelled examples — through multiple layers of mathematical operations that identify progressively higher-level features.
A chest X-ray AI trained on hundreds of thousands of labelled images learns to recognise the visual signatures of pneumothorax, pleural effusion, consolidation, and nodules. A retinal imaging AI learns to identify the microaneurysms, haemorrhages, and neovascularisation characteristic of diabetic retinopathy. The algorithm does not reason in the way a clinician reasons — it identifies statistical patterns — but when trained on high-quality, representative data, its pattern recognition can approach or exceed average radiologist performance on specific tasks.
AI in imaging is applied across three main functions:
Detection: Identifying whether an abnormality is present. AI detection algorithms are particularly valuable as a second reader or safety net, flagging studies that may have been missed.
Classification: Characterising the nature of a detected abnormality. AI classification might determine whether a lung nodule is likely benign or malignant, or grade the severity of diabetic retinopathy.
Segmentation: Precisely delineating the boundaries of anatomical structures or lesions — for example, measuring tumour volume or quantifying organ size. Automated segmentation saves significant time in applications like radiation therapy planning and oncology follow-up.
Specific Use Cases With Clinical Evidence
Chest X-Ray Screening
Chest X-ray AI has the largest body of published evidence of any imaging AI application. Multiple algorithms have demonstrated sensitivity and specificity for common findings — pneumonia, pleural effusion, cardiomegaly, pneumothorax — comparable to or exceeding general radiologists in controlled studies.
In resource-constrained settings with radiologist shortages, chest X-ray AI has been evaluated as a tool for prioritising urgent cases, enabling a single radiologist to manage higher volumes. AI-powered tuberculosis screening on chest X-rays is being evaluated or deployed in several high-burden, low-resource countries where radiologist access is limited.
Diabetic Retinopathy Screening
AI-based diabetic retinopathy screening using fundus photography is one of the most clinically mature AI imaging applications. IDx-DR (now Digital Diagnostics) was the first AI device to receive FDA De Novo authorisation for autonomous diagnosis (in 2018) — capable of determining whether referral is needed without requiring a clinician to interpret the image.
The application is compelling: diabetic retinopathy is highly prevalent, treatable if caught early, and currently under-screened because of the requirement for trained ophthalmologist review of fundus images. AI autonomous screening changes this by enabling primary care providers to conduct screening without immediate ophthalmologist involvement, dramatically expanding access.
Lung Nodule Management
Lung nodule detection and characterisation AI has been commercially available since the mid-2010s. These tools detect nodules on CT scans, measure their volume and density, and recommend management pathways based on validated guidelines such as Lung-RADS or Fleischner Society criteria. The clinical value is in reducing miss rates and providing consistent, guideline-concordant follow-up recommendations.
Computational Pathology
Digital pathology — the scanning of histological slides to produce high-resolution digital images — creates an analogous opportunity to radiology AI. Deep learning algorithms for digital pathology slides can detect cancer in lymph node sections, grade prostate cancer (Gleason grading), and quantify biomarker expression in tumour tissue. Several computational pathology products have received regulatory clearance, and integration with laboratory information systems and PACS is an active area of development.
Integration with PACS
For AI to function in a clinical radiology workflow, it must integrate with the PACS. The practical integration architecture typically involves:
- A DICOM study arrives in the PACS from the imaging modality
- The PACS notifies the AI platform (or the AI platform monitors for new studies via DICOM C-FIND or DICOMweb)
- The AI platform retrieves the study, applies the algorithm, and generates a DICOM structured report or overlay with findings
- The results are returned to the PACS and appear in the radiologist's reading workflow, either as annotations on the images or as a separate findings summary
Many PACS vendors now provide AI marketplaces or integration frameworks that simplify the deployment of third-party AI algorithms. The Nuance AI Marketplace, Philips IntelliSpace Portal, and similar platforms enable multiple AI applications to be connected to a single PACS infrastructure.
The Radiologist Augmentation vs Replacement Debate
The question of whether AI will replace radiologists has attracted considerable public and professional attention. The current evidence and the practical realities of clinical practice both point strongly towards augmentation rather than replacement — at least for the foreseeable future.
Current AI tools are narrow specialists. An algorithm trained to detect pneumothorax is not applicable to reading abdominal MRI. An algorithm that performs well on chest X-rays from one scanner type may not generalise to images from different equipment in a different population. The radiologist's role extends far beyond pattern recognition in images: it includes integrating clinical context, correlating multiple modalities, communicating with clinical teams, and making complex diagnostic judgments in ambiguous cases. None of these is within the current scope of deployed AI.
What AI does change is the workflow. AI triage tools that identify critical findings — intracranial haemorrhage, large vessel occlusion, pneumothorax — can reorder the radiologist's worklist so that the most urgent cases are addressed first. This is particularly valuable in high-volume departments where stroke or haemorrhage cases might otherwise wait behind a queue of routine studies.
Accuracy and Bias Considerations
The reported accuracy of medical imaging AI must be interpreted carefully. Performance metrics from published validation studies do not always translate to real-world deployment, for several reasons:
Dataset bias: If the training data comes predominantly from one type of scanner, one patient demographic, or one clinical presentation, the algorithm may perform poorly on images from different scanners, different populations, or different presentations. Chest X-ray algorithms trained on adult populations may perform poorly on paediatric images.
Reference standard quality: AI performance is measured against human-labelled reference standards, which are themselves imperfect. An algorithm cannot perform better than the quality of the labels it was trained and tested on.
Demographic disparities: Several studies have documented that commercial AI algorithms perform less well on images from underrepresented demographic groups. This is an active area of regulatory scrutiny and vendor accountability.
Adoption Barriers
Despite the evidence base and regulatory approvals, AI adoption in clinical radiology remains uneven. Key barriers include the cost of PACS integration and per-study licensing fees, institutional procurement and governance processes, radiologist scepticism about vendor performance claims, and the challenge of prospective validation in local patient populations before deployment.
FZ Consulting LLP supports healthcare organisations in evaluating, procuring, and integrating AI in medical imaging — from vendor assessment to PACS integration architecture. Contact our team to discuss your radiology AI programme.